A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study

Table 1 Baseline demographics, ocular and disease characteristics for patients with nAMD treated with ranibizumab (ITT Population^a)

Characteristics	ITT Population (n = 152)
Mean (SD) age, years	71.6 (10.8)
Gender, male, n (%)	98 (64.5)
Mean (SD) nAMD duration, months	5.5 (17.3)
Proportion of patients with nAMD duration ≤3 months, %	82.9
Mean (SD) BCVA, letters	47.5 (20.0)
Mean (SD) CRT, μm	385 (131.9)
Color fundus photography, n (%)
Haemorrhage	87 (58.0)
PED	55 (36.7)
SRF	77 (51.3)
Scar	24 (16.0)
CNV type, n (%)	141 (98.6)
100% classic/predominantly classic	11 (7.8)/ 41 (29.1)
Minimally classic/occult with no classic component	55 (39.0)/ 34 (24.1)

BCVA best-corrected visual acuity, CNV choroidal neovascularisation, CRT central retinal thickness, ITT intent-to-treat, n number of patients, nAMD neovascular age-related macular degeneration, SD standard deviation
^aDefined as patients who had baseline assessment, received at least 1 dose of observational drug and had at least 1 post-baseline assessment of the effectiveness variables. Data for BCVA and CRT was not available for 1 patient

ISSN: 1471-2415